Impact of Molecular Imaging on the Diagnosis of Dementia Subtypes

2021 ◽  
Vol 104 (12) ◽  
pp. 1873-1880

Objective: To evaluate the impact of positron emission tomography with ¹⁸F-FDG, ¹¹C-PiB, and ¹⁸F-THK 5351 on the diagnosis of Alzheimer’s disease, primary tauopathies, and other dementia subtypes. Materials and Methods: The authors recruited 30 patients with varying degrees of cognitive impairment that included 14 males and 16 females, aged 50 to 77 years and with a mean age ±SD: 66.6±6.9 years). All patients underwent ¹⁸F-FDG, ¹¹C-PiB, and ¹⁸F-THK 5351 PET/CT scans. Quantitative and visual analyses of the PET images were performed and reported back to the neurologists responsible for the initial diagnoses. Outcome measures were changed between pre- and post-PET clinical diagnoses and treatment. Results: The primary diagnoses changed after the disclosure of ¹⁸F-FDG, ¹¹C-PiB, and ¹⁸F-THK 5351 PET scan results in 18 of 30 patients (60%) and was able to resolve 20 of 21 (95.2%) pre-PET diagnostic dilemmas. No new diagnostic dilemmas were created. All changes in clinical diagnoses were accompanied by changes in treatment plan. PET imaging results confirmed the initial diagnoses of six patients. Conclusion: Combined ¹¹C-PiB, ¹⁸F-THK 5351, and ¹⁸F-FDG-PET are of additional diagnostic value over standard diagnostic work-up, especially in diagnostic dilemmas or difficult-to-diagnose dementia patients. Keywords: ¹⁸F-FDG; ¹¹C-PiB; ¹⁸F-THK 5351; Positron emission tomography; Tauopathy

2020 ◽  
Vol 17 (4) ◽  
pp. 1877-1879
Author(s):  
A. Allwyn Gnanadas ◽  
S. Sathishbabu ◽  
N. Shankar

Tumors, abnormally growing cells when identified in our body it is treated with appropriate medication. Anyway the impact of the medication on tumor cells is constantly disregarded. Ordinary tests however appear to be encouraging, the expense and the hazard included is gigantic. Post assessment along these lines should be exceptionally refined to create results fast and accurate. Fused imaging, a combination of PET scan and CT scan with suitable processing is utilized to gauge the volume of the tumor without influencing the subject under investigation.This strategy gives a promising post assessment results on the tumor cell that was under examination. The status of the tumor is also updated at regular intervals with simply imaging the subject at comfort.


2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Lei Peng ◽  
Jinze Li ◽  
Chunyang Meng ◽  
Jinming Li ◽  
Chengyu You ◽  
...  

Abstract Objective This article aims to evaluate the diagnostic value of 68Gallium-PSMA positron emission tomography/computerized tomography (68Ga-PSMA PET/CT) for lymph node (LN) staging in patients with prostate cancer (PCa) by a meta-analysis of diagnostic tests. Methods We systematically retrieved articles from Web of Science, EMBASE, Cochrane Database, PubMed. The time limit is from the creation of the database until June 2019, and Stata 15 was used for calculation and statistical analyses. Results Sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR), diagnostic odds ratio (DOR) and 95% confidence intervals (CI) be used to evaluate the diagnostic value. A total of 10 studies were included in our meta-analysis, which included 701 individuals. The results of each consolidated summary are as follows: sensitivity of 0.84 (95% CI 0.55–0.95), specificity of 0.95 (95% CI 0.87–0.98), PLR and NLR was 17.19 (95% CI 6.27, 47.17) and 0.17 (95% CI 0.05–0.56), respectively. DOR of 100 (95% CI 18–545), AUC of 0.97 (95% CI 0.95–0.98). Conclusion Our study demonstrates that 68Ga-PSMA PET/CT has a high overall diagnostic value for LN staging in patients with moderate and high-risk PCa. But our conclusions still require a larger sample size, multi-center prospective randomized controlled trial to verify.


2005 ◽  
Vol 23 (28) ◽  
pp. 6846-6853 ◽  
Author(s):  
Didier Lardinois ◽  
Walter Weder ◽  
Marina Roudas ◽  
Gustav K. von Schulthess ◽  
Michaela Tutic ◽  
...  

Purpose The aim of this prospective study was to assess the incidence and the nature of solitary extrapulmonary [18F] fluorodeoxyglucose (FDG) accumulations in patients with non–small-cell lung cancer (NSCLC) staged with integrated positron emission tomography and computed tomography (PET/CT) and to evaluate the impact on management. Patients and Methods A total of 350 patients with NSCLC underwent whole-body PET/CT imaging. All solitary extrapulmonary FDG accumulations were evaluated by histopathology, further imaging, or clinical follow-up. Results PET/CT imaging revealed extrapulmonary lesions in 110 patients. In 72 patients (21%), solitary lesions were present. A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary. Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%). The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each. Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture. Conclusion Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.


2019 ◽  
Vol 29 ◽  
pp. S197-S198
Author(s):  
M. Nørgaard ◽  
M. Ganz ◽  
C. Svarer ◽  
V.G. Frokjaer ◽  
D.N. Greve ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document